主要文件

查看所有文档

Y0001034

利奈孕酮

Name: 利奈孕酮
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

Lynestrenol, (17α)-19-Norpregn-4-en-20-yn-17-ol

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₀H₂₈O

化学文摘社编号:

52-76-6

分子量:

284.44

UNSPSC Code:

41116107

NACRES:

NA.24

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

lynestrenol

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O[C@@]1([C@@]2([C@H]([C@H]3[C@@H]([C@H]4CCCC=C4CC3)CC2)CC1)C)C#C

InChI

1S/C20H28O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h1,6,15-18,21H,4-5,7-13H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1

InChI key

YNVGQYHLRCDXFQ-XGXHKTLJSA-N

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Lynestrenol for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

法规信息

涉药品监管产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

[Hormonal contraception and cervix of the uterus pathology].

m A Dzhangidze et al.

Georgian medical news, (145)(145), 21-25 (2007-05-26)

The effect of hormonal contraception on cervix of the uterus of young nullipara women with ectopia was investigated. Cohort study was carried out by using simple blind method. By means of statistical data manipulation correlation between the application of hormonal

Regressive liver adenomatosis following androgenic progestin therapy withdrawal: a case report with a 10-year follow-up and a molecular analysis.

Magali Svrcek et al.

European journal of endocrinology, 156(6), 617-621 (2007-05-31)

The relationship between sex hormones and hepatocellular adenoma development is well established. On the contrary, their contribution to liver adenomatosis (LA) development is still a debatable issue. Recently, inactivating mutations of hepatocyte nuclear factor-1alpha (HNF-1alpha) transcription factor gene or activating

Two routes of hormonal replacement therapy in symptomatic menopausal women after kidney transplantation.

Bronisława Pietrzak et al.

Neuro endocrinology letters, 27(3), 387-391 (2006-07-04)

The assessment of efficacy and safety of two regimens of hormonal replacement therapy (HRT) in women after kidney transplantation with climacteric symptoms. Combined transdermal or transdermal-oral hormonal replacement therapy was administered to 86 kidney-transplanted women, aged 31-52 years, with moderate

查看所有相关文献

全球贸易项目编号

货号	GTIN
Y0001034	04061833796856